We examined trends in the treatment and survival in a population-based sample of white patients diagnosed with local-stage and regional-stage cutaneous melanoma in 1995, 1996, or 2001, treated in communities across the USA with vital status follow-up through 2007. White patients, aged 20 years or older with invasive cutaneous melanoma, were identified from the Surveillance, Epidemiology and End-Results population-based registries. Hospital and pathology records were reabstracted and physicians were asked to verify the provided therapy. The percentage of patients receiving lymph node biopsies increased over time. Sentinel lymph node biopsy increased between 1995 and 2001 from 5 to 32% for men and from 9 to 35% for women. The use of chemotherapy, hormonal therapy, and immunotherapy changed little. Facilities with approved residency training programs were more likely to perform lymph node dissections, to perform sentinel lymph node biopsy, and to treat patients more aggressively than were facilities without such programs. Men were significantly more likely than women to die of cutaneous melanoma. In multivariable survival analysis, after adjusting for age, Charlson score, and surgical margins, survival did not change significantly over this time. Deaths were associated with increasing tumor thickness for men and women. Surgical treatment of local or regional melanoma became more extensive over time with fewer local excisions and more lymph node dissections, but with little change in adjuvant therapy. Survival was associated with tumor thickness. Early detection when the tumor thickness is less may decrease mortality. Future research should especially target decreasing the disparity in survival between men and women.
Introduction
Cutaneous melanoma incidence has been increasing over the past 30 years from 7.9/100 000 in 1975 to 23.1/100 000 in 2008 [1] . Incidence rates increase with age and are higher in women until the age of 50 years, when the rates become higher in men. Cutaneous melanoma is much more common in non-Hispanic whites than in blacks. During 2001 During -2007 , approximately 84% of these cancers were localized at diagnosis, 8% were regional, 4% were distant, and 4% were unstaged. The 5-year relative survival rates have increased over time, from 83% for patients diagnosed between 1975 and 1979 to 93% for patients diagnosed between 2001 and 2007. The rates for the time period 2001-2007 show a 98% 5-year relative survival for patients diagnosed with localized disease and a 61% 5-year survival for patients with regional disease. In 2011, estimated 70 230 cases of cutaneous melanoma will be diagnosed and 8790 people will die of melanoma [2] .
The primary treatment for melanoma is surgery with wide excision of the tumor. The recommended margins depend on the thickness of the tumor (http://www.nccn.org/profes sionals/physician_gls/f_guidelines.asp). Treatment recommendations for more extensive disease include interferon-a, radiation, vaccines, or isolated limb profusion with melphalan. High-dose interferon has been shown to improve disease-free survival, and two of the three studies of high-dose interferon showed an overall survival advantage [3] [4] [5] . However, melanoma with distant spread at diagnosis is rarely curable http://www.cancer.gov/cancer topics/pdq/treatment/melanoma/HealthProfessional/page5.
The patterns of care study data of the National Cancer Institute (NCI) allow for the examination of trends over time in the distribution of cutaneous melanoma by anatomical site, therapy provided, the characteristics of the medical facility where the primary treatment was given, and the survival of patients with localized and regional disease. These population-based samples of cases were diagnosed in 1995, 1996, or 2001.
Methods
NCI's Surveillance, Epidemiology and End-Results (SEER) program includes a set of population-based registries that collect data on all cancer cases occurring in defined geographic areas. From 1992 to 1999, SEER data covered 14% of the US population; coverage increased to 26% in 2000 http://seer.cancer.gov/about/. SEER collects detailed information on tumor characteristics, demographics, and treatment and maintains follow-up of all registered cases. The data are primarily abstracted from hospital records, surgical centers, and radiation facilities. As adjuvant therapy is most often provided in an outpatient setting, NCI annually selects certain cancer sites and supplements the routine data abstraction with patterns of care studies. In addition, to reabstract the data, each patient's physician was asked to verify the treatment provided. These physicians were also asked whether other physicians might have provided care and, if so, the newly identified physicians were then contacted. To assure consistency of abstracting and coding, the supervising abstractor from each registry attended a central training.
The current data include white patients, who were 20 years or older and diagnosed with local or regional melanoma in 1995, 1996, or 2001. Patients were ineligible if they had previously been diagnosed with cancer other than nonmelanoma skin, were diagnosed on the death certificate or at autopsy, or were diagnosed simultaneously with a second cancer. African-American patients were not sampled because of their low incidence rate of melanoma. The nodal biopsy technique performed on each patient was independently abstracted from their medical record and did not rely on the information provided by cancer registry data. Patients were identified as having a sentinel lymph node biopsy (SLNB) if the medical record provided any indication of the procedure and was recorded regardless of any subsequent lymph node dissection (e.g. complete nodal dissection) performed. In 1995, 1996, and 2001, a total of 262, 751, and 1200 patients, respectively, were identified from participating registries. The registries participating in the patterns of care studies changed over time. As this study focused on trends over time, we limited the registries to those participating in at least two of the three years (the metropolitan areas of San Francisco, San Jose/Monterey, Atlanta, Detroit, Seattle, Los Angeles County, and the states of Connecticut, Iowa, New Mexico, and Utah). This excluded an additional 479 cases.
Bivariate analyses were carried out to determine the association between certain tumor characteristics and clinical, nonclinical, treatment variables, and the year of diagnosis. All estimates were weighted to reflect the population from which the sample was drawn. The sample weights, calculated as the inverse of the sampling proportion for each sampling stratum (defined by SEER registry, white Hispanic/white non-Hispanic ethnicity and sex), were used to obtain estimates that are representative of all eligible Caucasians melanoma patients in the study areas. We used the statistical software SAS and SUDAAN (Research Triangle Institute, Research Triangle Park, North Carolina, USA). The SUDAAN software allows for use of sample weights and adjusts the standard errors appropriately.
Follow-up was available through 31 December 2007. In a multivariate Cox proportional hazard model, we examined melanoma-specific mortality by sex adjusting for age group, Charlson score, tumor thickness, margins, and the year of diagnosis. All tests were two sided.
Results

Patient and tumor characteristics
In 2001, less than 32% of men but more than 48% of women were diagnosed with localized or regional melanoma at 49 years or younger (P < 0.0001; Table 1 ). Between 1995 and 2001, the percentage of patients who had no insurance decreased (P = 0.056). The percentage of patients treated in a facility with an approved residency training program, dropped from approximately 60 to 50%. The percentage of patients classified as 'malignant melanoma, not otherwise specified', increased and the percentage reported to have the superficial spreading histology decreased.
Treatment
The primary treatment for local or regional melanoma was surgery ( Table 2) . A substantial increase in lymph node sampling occurred over the time period (P < 0.0001). The use of sentinel node biopsy increased significantly between 1995 and 2001(P < 0.0001). In 1995, 5.1% of men and 9.2% of women had sentinel node biopsies compared with approximately one-third of patients diagnosed in 2001. The surgical margins were abstracted from pathology report or if not stated there, recorded from the operative report. Surgical margins were not stated nor unknown for approximately 40% of men diagnosed in 1995 and 42% of women; this dropped to 15%, for men (P < 0.0001) and 13% for women in 2001 (P < 0.0001). Tumor margins increased more for men than women over time, although the percentage of patients with margins of 2 cm or greater increased in 1996 and decreased in 2001.
Few patients received chemotherapy or immunotherapy and radiotherapy was rare. More than 98% of patients with localized disease received surgery as their only treatment (data not shown). Patients (27, 35, and 22%) with regional disease received chemotherapy, hormonal therapy, and/or immunotherapy in 1995, 1996, and 2001, respectively. In all years, interferon-a was the most frequent agent given for the treatment of regional melanoma. In 1995, slightly more than 26% of patients with regional-stage melanoma received interferon alone or with other agents; this decreased to approximately 21% in 1996 and 2001. Although adjuvant therapy varied by stage it did not vary by sex within stage of disease.
Tumor thickness
Patients with a tumor thickness of more than 1 mm were more likely to have a lymph node dissection (P < 0.0001; Table 3 ). The use of sentinel node biopsy increased significantly between 1995 and 2001 for all categories of reported tumor thickness and was significantly associated with tumor thickness (P < 0.0001).
Recording of margin status increased over time and with increasing tumor thickness. Patients diagnosed in 2001 with thin melanomas (< 0.7 mm) were more likely to have a margin of 1 cm or more (37%) compared with those with tumors more than1.0-mm thickness (11%; P < 0.0001).
Site of melanoma
The percentage and technique of lymph node biopsy varied by the anatomical location of the melanoma. The percentage of patients who received lymph node dissection increased between 1995 and 2001 for all anatomic locations (P < 0.03). However, the location of the melanoma influenced the technique of node biopsy ( Fig. 1) . In 1995, patients with melanomas on the lower limbs or hips were somewhat more likely to have lymph node sampling than were patients with melanomas on other parts of the body and these patients were much more likely to have a sentinel node biopsy (P < 0.04). By 2001, there were small differences in the use of sentinel node biopsy by location on the trunk, upper limbs, and shoulder, or lower limbs and hips; however, those with melanomas located on the head and neck were less likely to have a lymph node biopsy (P = 0.058), particularly using the sentinel node technique (P = 0.005). Over time, the percentage of patients receiving lymph nodes biopsies increased (Fig. 2 ). Despite this, only patients with melanoma on the trunk of the body had an increase in positive nodes; 1% in 1995 to 7% in 2001 (P < 0.001).
Healthcare factors
We examined tumor characteristics and treatment by the presence of an approved residency training program in the treatment facility (Table 4) . Over time, the percentage of patients categorized histologically as 'malignant melanoma, not otherwise specified', increases, but was not differentiated by sex. However, between 1995 and 2001, facilities with no approved residency training program had a significantly larger increase (P = 0.01). The number of nodes examined increased in both types of facilities, but those with a residency training program generally examined nodes more often (P < 0.001). In each year of the study, facilities with a residency training program performed sentinel node biopsies more frequently than those without residency training (P < 0.01). In 2001, nearly twice as many patients treated in facilities without a training program had a margin status not stated nor unknown, 18 versus 10% (P < 0.01). In addition, more were recorded as 'completely excised' without further specificity in hospitals with no residency training program (40%) than in hospitals with a program (25%; P < 0.0001).
Survival
In a Cox proportional hazards model, we examined cutaneous melanoma mortality for men and women separately adjusting for age, Charlson comorbidity score, tumor thickness, margin status, and the year of diagnosis (Table 5) . Mortality from melanoma for men increased significantly with a tumor thickness of 0.7 mm or greater and for women with a tumor thickness of greater than 1 mm. Charlson score, margin status, and year of diagnosis were not significantly related to melanoma-specific mortality for either men or women.
Discussion
This study offered an opportunity to examine trends in treatment, the use of adjuvant therapy, and survival in a population-based sample of patients with local or regional cutaneous melanoma treated in communities throughout A meta-analysis of three randomized clinical trials comparing different surgical margins reported that the surgical margin around the primary melanoma should not be less than 1 cm [6] . A subsequent meta-analysis that included two additional randomized trials determined that there may be insufficient data to conclude that narrow margins are not inferior to wider margins [7] . The percentage of patients with tumor margins not reported or unknown has decreased substantially over time, suggesting an increase in attention to margin status. By 2001, 86% of the patients had their margin status recorded. However, only 26% of the pathological margins were reported as being more than 1 cm with another 25% being 1 cm or more, and 33% reported as being uninvolved but not otherwise specified. Type of node biopsy by location of primary cutaneous melanoma and year of diagnosis. Vertical axis begins at 50%. LND, lymph node dissection. Nodal status by location of primary cutaneous melanoma and year of diagnosis. Vertical axis begins at 50%.
Trends in treatment and survival Harlan et al. 551 Thomas et al. [8] reported that patients with melanomas of 2 mm or greater thickness had a significantly greater risk of locoregional recurrence if the melanoma had a margin of 1 cm compared with a margin of 3 cm. In this study, we do not have the data to examine recurrence, but in 2001 only 3.5% of patients with tumor thicknesses greater than 1 mm had margins of greater than 3 cm, whereas 28.6% had margins of 1.01-2 cm.
Sentinel lymph node biopsy
The use of SLNB began in the early 1990s after the development of the technique and publication of early results [9, 10] . SLNB increased between 1995-1996 and 2001 in all categories of tumor thickness that we examined. Although sentinel node biopsy is important in staging, a multicenter selective lymphadenectomy trial analysis indicated that in patients with intermediate thickness primary melanomas, sentinel node biopsy was not associated with an increased melanoma-specific survival when compared with the observation group [11] .
In this study, we found that the tumor thickness and technique of lymph node biopsy were significantly associated with melanoma mortality in both men and women. There was also a strong correlation between sentinel node biopsy and tumor thickness. However, the association cannot be attributed to the technique of nodal sampling because patients with thicker tumors, and therefore more likely to die, were also significantly more likely to have traditional sampling.
Carlson et al. [12] reported that patients with melanoma of the head or neck and with an increased tumor thickness were more likely to have false-negative sentinel lymph nodes. We found that patients with melanoma of the head and neck were less likely to have a sentinel node biopsy than were patients with melanoma of other sites. It is possible that physicians chose not to use SLNBs because of the more variable lymphatic drainage patterns for tumors of the head and neck.
Likelihood of positive nodes
Investigators have reported an increase in positive nodes with an increased tumor thickness [11, 13] . In this population-based sample, we found that as tumor thickness increased, the percentage of patients who had lymph nodes sampled increased, as did the percentage with positive nodes.
Nonsurgical therapy
For patients with limited resectable disease (> 1-mm thick and negative lymph nodes) the National Comprehensive Cancer Network guidelines suggest interferon-a as an option and advise that interferon-a or radiation should be considered for patients with positive nodes (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).
A meta-analysis published in 2002 reported that the randomized clinical trials did not support a 'clear benefit'
for interferon-a [14] . Controversy still surrounded the use of interferon-a in the treatment of stage IIb and III as evidenced by a point-counterpoint published in early 2008 [15, 16] . The lack of consensus regarding the use of interferon-a was highlighted by the geographic variation in our data. In one geographic area, no patient in any of the 3 years received interferon-a, whereas in another area 11% received interferon-a in 1995, although this decreased to 6% in 2001. However, a 2010 meta-analysis of interferon-a studies in high-risk patients showed a significant increase in disease-free and overall survival [17] . These findings may influence clinical practice moving it toward a consensus.
Despite the guidelines suggesting that radiation should be considered for patients with positive lymph nodes, in all 3 years only approximately 1% of patients received radiation. This low rate of use appears to reflect some concern regarding its benefit. Several registries reported that no melanoma patient with localized or regional disease had been given radiation in any of the 3 years, whereas in the registry reporting the highest use only approximately 3.5% of patients received radiation in 1995 and 1996.
Healthcare facility
Facilities with approved residency training programs generally treated melanoma patients more aggressively than did facilities without such programs, performed more lymph node dissection, used the sentinel node biopsy technique, recorded specifics on margin status measurements, and were more aggressive in their use of nonsurgical therapy. Pennie et al. [18] reported that Medicare patients diagnosed with melanoma by a dermatologist had earlier stage disease at diagnosis and better survival. However, we were unable to determine the specialty of the residency program and it is likely that the majority of these programs were not dermatologic residencies.
Survival
A study of survival following cutaneous melanoma in England and Wales found survival increased from the late 1980s to the late 1990s, but men had poorer survival compared with women [19] . A long-term follow-up study in Germany reported that men, older age, melanoma of the head or truck, and patients with tumors of higher pT and pN had poorer survival [20] . In our population-based study, men also had poorer survival. We found that tumor thickness was associated with an increased mortality from cutaneous melanoma. Although being treated in a facility with a residency training program was associated with more aggressive therapy, it was not associated with survival in the multivariate analyses and was excluded from the final model. Perhaps, the lack of association in the model was due to patients with poorer prognostic factors selecting, or being referred to, facilities with residency training programs. An analysis of melanoma patients in the SEER-Medicare data diagnosed between 1988 and 1999 reported patients with a higher stage, increased tumor thickness, certain histologies, tumor locations, earlier year of diagnosis, older age, male sex, and increased comorbidity score were at an increased risk of cancer mortality [21] . However, we cannot directly compare these two studies, as we included only white adult patients, diagnosed in the mid-1990s and early 2000s with localized or regional disease. The SEERMedicare study included patients aged 65 years or older from all racial/ethnic groups.
Limitations
We do not have information on patient preference for therapies. It is possible that some patients preferred a wider excision with the hope of avoiding adjuvant therapy or additional surgery. In addition, we used the best available data for margin status, which might have been based on clinical assessment and influenced our findings by increasing the apparent margins. Recent research indicates that physicians do a poor job of estimating size of margins of tumor based on visual inspection. Clausen and Brady [22] reported a discrepancy between clinical and pathological margins with pathologic margins being 90% of the clinical margins. We also do not know the specialty of the diagnosing and/or treating physician. This might have influenced the therapy selected. However, this is a population-based sample of patients being treated in the community throughout the USA and should provide a picture of therapy, trends in that therapy over 7 years, and survival through 2007.
Conclusion
With the exception of nodal sampling and margin status, therapy for localized and regional melanomas has not changed significantly between 1995 and 2001. The use of adjuvant therapy in melanoma patients was minimal and has, in fact, decreased over time. It is clear that a consensus on the use of such therapies for these patients treated in a community setting has not been reached. In addition, after adjusting for demographic, tumor characteristics, and surgical margins, mortality from melanoma has not changed. Future research should include a focus on the reasons for the continuing poorer survival among men and on clinical trials for patients with melanoma to identify the appropriate therapy.
